OncoMatch/Clinical Trials/NCT07119463
Effect of Goal-Oriented Albumin Infusion on Postoperative Complication Management in Gastric Cancer Surgery
Is NCT07119463 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Human Serum Albumin Infusion for LAT Group and Human Serum Albumin Infusion for HAT Group for postoperative hypoalbuminemia.
Treatment: Human Serum Albumin Infusion for LAT Group · Human Serum Albumin Infusion for HAT Group — This study aims to evaluate the impact of goal-oriented albumin infusion on short-term postoperative outcomes in gastric cancer patients. It is a single-center, prospective, non-randomized controlled study. Patients are divided into two groups: the experimental group receives albumin infusion when serum albumin levels fall below 25 g/L, while the control group receives albumin infusion when levels fall below 30 g/L. The primary endpoint is the incidence of complications graded Clavien-Dindo III or above within 30 days post-surgery. Secondary endpoints include nutritional recovery, gastrointestinal function recovery, hospital stay duration, and overall complication rates. The study seeks to optimize perioperative albumin management strategies and improve clinical outcomes.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Gastric Cancer
Disease stage
Required: Stage I, II, III (TNM)
Excluded: Stage DISTANT METASTASIS
preoperative CT assessment of TNM stage I to III and undergoing laparoscopic gastric cancer surgery or open gastric cancer surgery
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: radiation therapy
Lab requirements
Blood counts
preoperative hemoglobin <70g/L excluded
Kidney function
renal insufficiency (serum creatinine >133umol/L) excluded
Liver function
severe liver insufficiency (Child Pugh class B or C) excluded
Cardiac function
severe cardiac insufficiency (NYHA class III and above) excluded
serious basic diseases: such as severe liver insufficiency (Child Pugh class B or C), renal insufficiency (serum creatinine>133umol/L), severe cardiac insufficiency (NYHA class III and above), severe pulmonary insufficiency (preoperative blood gas analysis PaO2 ≤ 60mmHg)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07119463 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage I or II or III is required.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages